- Open Access
Fluorometric determination of ethidium bromide efflux kinetics in Escherichia coli
© Paixão et al; licensee BioMed Central Ltd. 2009
- Received: 29 July 2009
- Accepted: 16 October 2009
- Published: 16 October 2009
Efflux pump activity has been associated with multidrug resistance phenotypes in bacteria, compromising the effectiveness of antimicrobial therapy. The development of methods for the early detection and quantification of drug transport across the bacterial cell wall is a tool essential to understand and overcome this type of drug resistance mechanism. This approach was developed to study the transport of the efflux pump substrate ethidium bromide (EtBr) across the cell envelope of Escherichia coli K-12 and derivatives, differing in the expression of their efflux systems.
EtBr transport across the cell envelope of E. coli K-12 and derivatives was analysed by a semi-automated fluorometric method. Accumulation and efflux of EtBr was studied under limiting energy supply (absence of glucose and low temperature) and in the presence and absence of the efflux pump inhibitor, chlorpromazine. The bulk fluorescence variations were also observed by single-cell flow cytometry analysis, revealing that once inside the cells, leakage of EtBr does not occur and that efflux is mediated by active transport. The importance of AcrAB-TolC, the main efflux system of E. coli, in the extrusion of EtBr was evidenced by comparing strains with different levels of AcrAB expression. An experimental model was developed to describe the transport kinetics in the three strains. The model integrates passive entry (influx) and active efflux of EtBr, and discriminates different degrees of efflux between the studied strains that vary in the activity of their efflux systems, as evident from the calculated efflux rates: = 0.0173 ± 0.0057 min-1; = 0.0106 ± 0.0033 min-1; and = 0.0230 ± 0.0075 min-1.
The combined use of a semi-automated fluorometric method and an experimental model allowed quantifying EtBr transport in E. coli strains that differ in their overall efflux activity. This methodology can be used for the early detection of differences in the drug efflux capacity in bacteria accounting for antibiotic resistance, as well as for expedite screening of new drug efflux inhibitors libraries and transport studies across the bacterial cell wall.
- Phosphate Buffer Solution
- Efflux Pump
- Efflux Rate
- Efflux System
Efflux pumps are major defensive components of the bacterial cell wall that actively extrude noxious compounds from the periplasm and/or cytoplasm, thereby decreasing their intracellular concentration [1, 2]. Active efflux of antibiotics by bacteria was first described in 1978 in Escherichia coli resistant to tetracycline  and, since then, it has been proven that the constitutive or inductive expression of these systems is responsible for the intrinsic and acquired resistance of many bacterial species to antimicrobials [4, 5]. Bacterial efflux pumps may be divided into five categories, according to their bioenergetics and structural characteristics: the A TP-B inding C assette (ABC) superfamily, the M ajor F acilitator S uperfamily (MFS), the R esistance N odulation cell D ivision (RND) family, the S mall M ultidrug R esistance (SMR) family and the M ultidrug A nd T oxic compound E xtrusion (MATE) family [5–7]. Efflux pumps may be specific for one substrate or recognize a wide range of structurally dissimilar and unrelated compounds, including several classes of antibiotics [7, 8]. In E. coli, the most common commensal Gram-negative bacterium of the human gut, at least nine proton dependent efflux pumps responsible for multidrug resistant (MDR) phenotypes have been described [2, 9–11]. Among these, the tripartite AcrAB-TolC system is recognized as the most important multi-component efflux system and is composed of: (i) AcrB, an inner membrane protein that functions as the transporter component of the pump; (ii) TolC, the protein that traverses the cell envelope and provides a conduit to the exterior; and (iii) AcrA, two periplasmic embedded membrane proteins that anchor TolC to the plasma membrane . The AcrAB-TolC system is responsible for the extrusion of substrates from the periplasm and/or the cytoplasm. The over-expression of this efflux system is a major cause of the MDR phenotype of clinical isolates, due to its ability to extrude several classes of antibiotics [2, 10, 13]. Although AcrAB-TolC is considered the most important efflux system of E. coli, other tripartite efflux pumps, such as the AcrEF-TolC can extrude similar substrates albeit at lower efficiency levels. Moreover, these pumps can be over-expressed when AcrAB is deleted or inactivated [8, 11, 13, 14].
Several methods have been used to detect and quantify the activity of bacterial efflux pump systems using radio-labeled, metal-labeled or fluorescent substrates to monitor their efflux in bacterial cells [15–21]. Bulk measurement techniques that use fluorescence spectroscopy yield a general understanding that represents the balance between entry and extrusion of a given substrate, which may result from the efflux activities of one or several pumps [17, 19], and where cell membrane permeability also plays an important role [11, 14]. Because the permeability to the substrate may be regulated by a decreased number of porins or by an increase of the lipopolysaccharide layer of the cell envelope [11, 14], the demonstration of efflux activity invariably involves the use of an agent that promotes a significant increase of substrate accumulated [19, 22, 23]. Unless the demonstration of the role of a specific efflux pump is readily made, i.e. by the quantification of the expression level of a specific transporter [11, 13], or by the use of mutants whose specific efflux pump has been deleted or inactivated , very little can be said about the role that any efflux pump system may play in the MDR phenotype of bacteria.
Recently, a semi-automated fluorometric method has been developed by us for the assessment of efflux pump activity in bulk bacterial cells . The method uses the common efflux pump substrate ethidium bromide (EtBr) that has been shown to be a particularly suitable probe for these studies. In fact it emits weak fluorescence in aqueous solution (external to the cell) and becomes strongly fluorescent when its concentration within the periplasm exceeds that of the aqueous solution due to its binding to cellular components . Such binding must be of a weak type if the agent is to serve as a useful probe for efflux, since later intercalation into DNA results in strong binding that precludes any dissociation of the substrate for efflux [16, 17]. This method can distinguish accumulation, which reflects the balance between influx and efflux, from efflux itself  and, therefore, has the potential for the study of the kinetics of EtBr transport. The method was developed using the wild-type E. coli K-12 AG100 as the bacterial model and the accumulation and efflux of EtBr was monitored by real-time fluorometry using the Rotor-Gene™ 3000 from Corbett Research (Sydney, Australia) [22–24]. The major innovation of this method is the simultaneous evaluation of efflux pump activity in vivo and on-line of a large number of samples, with the possibility to expose the same cell preparation to different environmental conditions in a single assay.
In the study to be described herein, this method has been used to define and parameterize a mechanistic experimental model that demonstrates the kinetics of EtBr influx and efflux by E. coli strains that differ in their capacity to extrude this molecule. The determination of the influx and efflux rates (k+ and k-, respectively) of a fluorescent substrate by the approach proposed allows the quantification of the cell overall efflux capacity. This information can be useful to interpret different phenotypes resulting from this efflux activity, including multidrug resistance in clinical bacterial strains.
The following bacteria were employed in this study: E. coli K-12 AG100 wild-type strain (argE3 thi-l rpsL xyl mtl Δ(gal-uvrB) supE44), containing a fully functional AcrAB-TolC efflux pump system; E. coli AG100A (ΔacrAB::Tn903 Kanr) with the AcrAB-TolC efflux pump system inactivated due to the insertion of the transposon Tn903 in the acrAB operon ; and E. coli AG100TET, a AG100 progeny strain, induced to high level of resistance to tetracycline (able to survive in 10 μg/ml of tetracycline, with an MIC of 12 μg/ml), as previously described, and over-expressing several efflux pumps, among which acrAB shows the highest expression level when exposed to high levels of tetracycline [11, 13]. E. coli K-12 AG100 and AG100A have been previously characterized and were kindly offered by Hiroshi Nikaido (University of California, Berkeley, California, USA) . Bacterial cultures were grown in Luria-Bertani (LB) medium at 37°C with agitation (220 rpm). Cultures of AG100A and AG100TET were supplemented with 100 μg/ml of kanamycin and 10 μg/ml of tetracycline, respectively.
Phosphate Buffered Solution (PBS), glucose, EtBr, kanamycin, ciprofloxacin, ofloxacin, chloramphenicol, erythromycin, tetracycline and chlorpromazine (CPZ) were purchased from Sigma-Aldrich Química SA (Madrid, Spain). EtBr solutions were stored at 4°C and protected from light. Tetracycline stock solution was prepared in methanol, whereas kanamycin, ciprofloxacin, ofloxacin, erythromycin and CPZ were prepared in distilled water and filtered with 0.22 μm syringe filters (Millipore Corporation, Bedford, USA). Chloramphenicol stock solution was prepared in ethanol. All working solutions were prepared in distilled water on the day of the experiment. LB medium was purchased from Difco (Detroit, Michigan, USA). Mueller-Hinton (MH) broth medium was purchased from Oxoid (Basingstoke, Hampshire, UK).
Determination of minimum inhibitory concentrations (MICs)
The MICs for EtBr, the efflux pump inhibitor (EPI) CPZ, kanamycin, ciprofloxacin, ofloxacin, chloramphenicol, erythromycin and tetracycline were determined by the broth microdilution method in 96-well microtitre plates according to the CLSI guidelines . Briefly, bacterial strains were incubated overnight in 5 ml of MH broth at 37°C with shaking at 220 rpm. Bacterial cultures were then diluted in PBS to a McFarland 0.5 turbidity standard. Aliquots of 0.05 ml were transferred to each well of the 96-well plate that contained 0.15 ml of each compound at concentrations prepared at 2-fold serial dilutions in MH broth medium. The plates were incubated at 37°C and the MIC results registered after 16-18 h. The MIC was defined as the lowest concentration of compound for which no growth was observed. In order to assure that the EPI did not compromise the cellular viability, the concentrations used in the following work did not exceed 1/2 of the MIC. The MIC for tetracycline was also calculated in the presence of CPZ at 1/2 of the MIC.
The semi-automated fluorometric method
(i) Accumulation assay
The accumulation of EtBr was carried out as previously described . Briefly, the E. coli strains were grown in 10 ml of LB medium until they reached a mid-log phase, which corresponded to an optical density at 600 nm (OD600) of 0.6. The bacteria were then centrifuged at 16,060 ×g for 3 minutes, the pellet washed twice with the same volume of PBS and the OD600 of the cellular suspension adjusted to 0.3. Glucose was added to the cellular suspension to a final concentration of 0.4% (v/v) and aliquots of 0.095 ml were transferred to 0.2 ml microtubes. EtBr was added in aliquots of 0.005 ml to obtain final concentrations that ranged from 1.0 to 6.0 μg/ml for E. coli K-12 AG100 and AG100TET and from 0.125 to 1.5 μg/ml for AG100A. The fluorescence was monitored in the Rotor-Gene™ 3000 at 37°C under the conditions described above. The effect of CPZ in the accumulation of EtBr was determined under conditions that optimize efflux (presence of glucose and incubation at 37°C). CPZ was used at concentrations that did not exceed 1/2 the MIC and the fluorescence was measured over a period of 60 minutes.
(ii) Efflux assay
The assessment of the efflux of EtBr was conducted as previously described . Briefly, the E. coli strains were loaded with EtBr under conditions that favor accumulation (no glucose, 25°C and presence of CPZ). When the maximum level of EtBr accumulation was reached (approximately 60 minutes), the bacteria were centrifuged (16,060 ×g for 3 minutes) and the medium was replaced by: i) PBS without glucose; ii) PBS containing glucose; and iii) PBS without glucose and with CPZ (control of minimum efflux). Aliquots of 0.1 ml were transferred to 0.2 ml microtubes and the assay was performed at 37°C with continuous measurement of fluorescence as described above. The efflux of EtBr is presented in terms of relative fluorescence, which is obtained from the comparison between the fluorescence observed for the bacteria in the presence or absence of glucose and the control in which the cells are exposed to conditions of minimum efflux (i.e., absence of glucose and presence of CPZ). Each experiment was conducted in triplicate and the results obtained did not vary.
Model to quantify EtBr efflux in E. coli
(i) Quantification of intracellular EtBr concentration
In order to assess the amount of EtBr extruded from the cells, one has to quantify the amount retained inside the cells. First, a calibration curve is determined that correlates the initial fluorescence of the buffer containing EtBr (FLo) with the corresponding EtBr concentration (varying from 0 to 6 μg/ml): [EtBr] intial = 0.1201 × FL0 + 0.0373(R = 0.99). Then, for each concentration tested, an EtBr accumulation assay was performed, as described above. To quantify the intracellular EtBr concentration, at the end of the accumulation assay, 0.6 ml of each EtBr containing buffer were separated from the cells by centrifugation at 16,060 ×g for 10 minutes and the supernatant filtered with 0.22 μm syringe filters from Millipore Corporation (Bedford, USA). The fluorescence of the cell free buffer was measured in the Rotor-Gene™ 3000 (FL(PBS+EtBr)filt non corrected).
Since some EtBr is retained by the filter itself, a correction factor must be used to account for this difference. Thus, the corrected fluorescence of the filtered buffer corresponds to (FL(PBS+EtBr)filt corrected). = 1.2289 × (FL(PBS+EtBr)filt non corrected). + 0.7032 (R = 0.99). The difference between the initial fluorescence of the EtBr containing buffer (FLo) and (FL(PBS+EtBr)filt corrected gives the fluorescence corresponding to the intracellular EtBr concentration. However, the fluorescence data from the transport assays measured experimentally still contains a component from the EtBr that remains in solution. Thus, each value of the experimental accumulation curve can then be corrected by subtracting the background corresponding to the fluorescence of the initial EtBr concentration, originating FLint exp corr. By plotting the previously determined EtBr intracellular concentration for the final value of FLint exp corr, for each initial EtBr concentration tested, a new relation is achieved: [EtBr]int = 0.022 × FLint exp corr+ 0.06 (R = 0.99), which allows the conversion of the experimental fluorescence data over time into intracellular EtBr concentration over time. The correlations shown here were determined for the wild-type E. coli K-12 AG100. Similar relations were determined specifically for the other two strains used (AG100A and AG100TET).
(ii) Mathematical and statistical analyses
The model was fitted to the experimental values ([EtBr]int vs t) using the software Table Curve™ 2D from Jandel Scientific - AISN Software STATISTICA, which allowed the determination of the values of the parameters describing the influx and efflux rates, k+ and k-, respectively. Three independent assays were conducted and the results shown are the average ± standard deviation. P-value from the ANOVA statistical test was calculated.
(iii) Model validation
The predictive model proposed was validated by comparing the experimental data obtained using E. coli K-12 AG100, AG100A and AG100TET cell suspensions incubated in the presence of different concentrations of EtBr and the curves generated by the model, using the k+ and k- constants determined as described above.
This methodology was used to corroborate the analysis of the data obtained with the semi-automated fluorometric method. Therefore, the samples from the accumulation and efflux assays, used in the semi-automated fluorometric method, were also analyzed by flow cytometry, in order to compare the results obtained with these two methodologies. Data acquisition and analysis were performed using a FACSCalibur™ (BD Biosciences, San Jose, CA, USA). EtBr was excited at 488 nm and the fluorescence detected through a 585 nm filter (FL-2 channel).
(i) Accumulation assay
E. coli strains were cultured in 10 ml of LB medium at 37°C and 220 rpm until an OD600 of 0.6. Aliquots of 1.0 ml were centrifuged at 16,060 ×g for 3 minutes, the supernatant discarded and the pellet washed twice with PBS. The OD600 of the bacterial suspension was adjusted to 0.3 using PBS without glucose. EtBr was added at a final concentration of 1 μg/ml and CPZ was added to a final concentration of 20 μg/ml. Following incubation at 25°C for 60 minutes, aliquots of 0.5 ml were taken for fluorescence measurement in the flow cytometer FACSCalibur™. Data was collected for at least 10,000 events per sample.
(ii) Efflux assay
After loading the bacteria with EtBr (1 μg/ml) in the presence of CPZ (20 μg/ml), the bacterial suspension was centrifuged at 16,060 ×g for 3 minutes. The supernatant was removed and the pellet resuspended in EtBr-free PBS, adjusting the OD600 to 0.3. Efflux was assessed in the presence and absence of glucose at 0.4% (v/v). Aliquots of 0.5 ml were taken after 2.5, 5, 15, 30 and 60 minutes after incubation at 37°C, for fluorescence measurement in the flow cytometer FACSCalibur™. Analyses were performed with an acquisition of at least 10,000 events per sample.
Detecting EtBr efflux mediated by E. coli efflux pump systems
MIC values of EtBr and several antibiotics for E. coli AG100, AG100A and AG100TET.
E. coli strains
TET + CPZ
Therefore, this methodological approach proved its usefulness for the demonstration of active efflux of EtBr in E. coli and the strategy developed allowed to differentiate influx (passive diffusion into the cell) from efflux activity (active efflux through pumps).
Modeling EtBr transport across E. coli cell wall
where [EtBr]initial = [EtBr]Total. When the E. coli cells are exposed to EtBr containing buffer (1 to 6 μg/ml for AG100 and AG100TET; 0.125 to 1.5 μg/ml for AG100A), the cells start to accumulate EtBr that enters by passive diffusion, with the efflux pump systems trying to balance this entry according to the kinetics presented in Figure 2. At these low concentrations, EtBr does not reach the cellular components in the cytoplasm to which it could bind irreversibly, being effluxed from the cytoplasm and periplasm by either single- or multi-component efflux systems [26, 27]. When the concentration of EtBr within the periplasmic space exceeds significantly its extrusion, EtBr is translocated beyond the inner plasma membrane where the medial sites of the cell contain nucleic acids to which the EtBr can intercalate almost irreversibly, after which extrusion is not possible [16, 17, 26, 27].
Influx (k+) and efflux (k-) rates for E. coli K-12 AG100, AG100A and AG100TET.
E. coli strains
0.0019 ± 0.0009
0.0173 ± 0.0057
0.0035 ± 0.0012
0.0106 ± 0.0033
0.0025 ± 0.0009
0.0230 ± 0.0075
The model proposed accurately describes the behavior of the three strains, showing a lower efflux rate for the AG100A strain when compared to the wild-type AG100 (P value = 0.0023), as a result of the inactivation of the AcrAB-TolC system in the mutant strain. For the AG100TET strain the model revealed a significantly increased efflux rate compared to the wild-type strain (P value = 0.0057). This result reflects the higher efflux activity in this tetracycline adapted strain due to the over-expression of efflux pumps, particularly of the AcrAB-TolC system [11, 13].
In this work we have applied the technical advantages of the semi-automated fluorometric method  for the development and application of an experimental model to describe and quantify the efflux pump activity in E. coli. The semi-automated fluorometric method affords the in vivo and on-line evaluation of the efflux pump activity by real-time fluorometry using the Rotor-Gene™ 3000, and represents an innovative technique when compared to other technologies . Based upon the differences of fluorescence that reflect differences on the EtBr concentrations outside and inside the cells, the technique provides a powerful tool for the real-time monitoring of efflux kinetics in bacterial cells. Moreover, it has potential for the identification of new efflux pump substrates, as well as new bacterial EPIs . A more fundamental application is the extension of this methodology to understand the transport kinetics of EtBr or other fluorescent substrates in bacterial cells.
We used such approach to differentiate and quantify EtBr transport in E. coli, and an experimental model was developed which parameterizes passive entry (influx) and active efflux of EtBr. The methodology developed allowed to detect differences in the EtBr efflux activity among strains that differ in their efflux pump expression, highlighting the importance of these systems in the extrusion from the cell of toxic compounds such as EtBr [6, 7, 10].
Although the experimental model presented was designed based upon a set of three canonic, isogenic strains, as a way to assess the method's sensitivity to differentiate their singular efflux activities, it can be applied to other E. coli strains or bacteria, since it is based on the overall transport of EtBr across the bacterial cell wall, which is common among bacteria [2, 7, 16, 22, 23]. It should be stressed however that it allows measuring the overall efflux activity rather than efflux related to a specific pump. For evaluation of the role played by a pump, a mutant specific for that pump must be used. The determination of influx and efflux rates for each of the strains to be analyzed opens new insights and opportunities for exploration of cell wall permeability, as well as for the control of the efflux activity in bacterial cells, representing a quantitative method to determine efflux activity. This approach may be used to elaborate a standardized data base for different reference strains relative to efflux activity (efflux rates), providing the means by which one can evaluate the resistance due to efflux pump activity in standardized conditions between laboratories. It represents a particularly suitable procedure for the assessment of efflux pump activity in MDR clinical isolates and screening for potential inhibitors of such activity. Such approaches may contribute to a better understanding of the bacterial efflux systems as a resistance mechanism and to design new therapeutic strategies against MDR bacterial infections .
This work was supported by grants EU-FSE/FEDER-POCI/SAU-MMO/59370/2004, EU-FSE/FEDER-PTDC/BIA-MIC/71280/2006 and PTDC/BIA-MIC/105509/2008 provided by Fundação para a Ciência e a Tecnologia (FCT) of Portugal. M. Martins and L. Rodrigues were supported by grants SFRH/BD/14319/2003 and SFRH/BD/24931/2005 (FCT, Portugal), respectively. C.C.C.R. de Carvalho and P. Fernandes acknowledge FCT for contract under Programme Ciência 2007.
- Li XZ, Nikaido H: Efflux-mediated drug resistance in bacteria. Drugs 2004, 64: 159-204. 10.2165/00003495-200464020-00004View ArticleGoogle Scholar
- Piddock LJ: Multidrug-resistance efflux pumps - not just for resistance. Nat Rev Microbiol 2006, 4: 629-636. 10.1038/nrmicro1464View ArticleGoogle Scholar
- Levy SB, McMurry L: Plasmid-determined tetracycline resistance involves new transport systems for tetracycline. Nature 1978, 276: 90-92. 10.1038/276090a0View ArticleGoogle Scholar
- Bambeke FV, Pagès JM, Lee VJ: Inhibitors of bacterial efflux pumps as adjuvants in antibiotic treatments and diagnostic tools for detection of resistance by efflux. Recent Patents Anti-Infect Drug Disc 2006, 1: 157-175. 10.2174/157489106777452692View ArticleGoogle Scholar
- Pagès JM, Masi M, Barbe J: Inhibitors of efflux pumps in Gram-negative bacteria. Trends Mol Med 2005, 11: 382-389. 10.1016/j.molmed.2005.06.006View ArticleGoogle Scholar
- Lomovskaya O, Zgurskaya HI, Totrov M, Watkins WJ: Waltzing transporters and 'the dance macabre' between humans and bacteria. Nat Rev Drug Discov 2007, 6: 56-65. 10.1038/nrd2200View ArticleGoogle Scholar
- Poole K: Efflux pumps as antimicrobial resistance mechanisms. Ann Med 2007, 39: 162-176. 10.1080/07853890701195262View ArticleGoogle Scholar
- Piddock LJ: Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev 2006, 19: 382-402. 10.1128/CMR.19.2.382-402.2006View ArticleGoogle Scholar
- Davin-Regli A, Pagès JM: Regulation of efflux pumps in Enterobacteriaceae: genetic and chemical effectors. In Antimicrobial resistance in bacteria. Edited by: Amabile-Cuevas CF. Norfolk, UK: Horizon Bioscience; 2007:55-75.Google Scholar
- Okuso H, Ma D, Nikaido H: AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants. J Bacteriol 1996, 178: 306-308.Google Scholar
- Viveiros M, Dupont M, Rodrigues L, Couto I, Davin-Regli A, Pagès JM, Amaral L: Antibiotic Stress, Genetic Response and Altered Permeability of E. coli . PLoS ONE 2007,2(4):e365. 10.1371/journal.pone.0000365View ArticleGoogle Scholar
- Pietras ZV, Bavro N, Furnham N, Pellegrini-Calace M, Milner-White EJ, Luisi BF: Structure and mechanism of drug efflux machinery in Gram negative bacteria. Curr Drug Targets 2008, 9: 719-728. 10.2174/138945008785747743View ArticleGoogle Scholar
- Viveiros M, Jesus A, Brito M, Leandro C, Martins M, Ordway D, Molnar M, Molnar J, Amaral L: Inducement and reversal of tetracycline resistance in Escherichia coli K-12 and expression of proton gradient-dependent multidrug efflux pump genes. Antimicrob Agents Chemother 2005, 49: 3578-3582. 10.1128/AAC.49.8.3578-3582.2005View ArticleGoogle Scholar
- Davin-Regli A, Bolla JM, James CE, Lavigne JP, Chevalier J, Garnotel E, Molitor A, Pagès JM: Membrane permeability and regulation of drug "influx and efflux" in enterobacterial pathogens. Curr Drug Targets 2008, 9: 750-759. 10.2174/138945008785747824View ArticleGoogle Scholar
- Greulich KO: Single molecule techniques for biomedicine and pharmacology. Curr Pharm Biotechnol 2004, 5: 243-259. 10.2174/1389201043376878View ArticleGoogle Scholar
- Jernaes MW, Steen HB: Staining of Escherichia coli for flow cytometry: influx and efflux of ethidium bromide. Cytometry 1994, 17: 302-309. 10.1002/cyto.990170405View ArticleGoogle Scholar
- Joux F, Lebaron P: Use of fluorescent probes to assess physiological functions of bacteria at single-cell level. Microbes Infect 2000, 2: 1523-1535. 10.1016/S1286-4579(00)01307-1View ArticleGoogle Scholar
- Kyriacou SV, Brownlow WJ, Xu XHN: Using nanopartical optics assay for direct observation of the function of antimicrobial agents in single live bacterial cells. Biochemistry 2004, 43: 140-147. 10.1021/bi0351110View ArticleGoogle Scholar
- Lomovskaya O, Bostian KA: Practical applications and feasibility of efflux pump inhibitors in the clinic - a vision for applied use. Biochem Pharmacol 2006, 71: 910-918. 10.1016/j.bcp.2005.12.008View ArticleGoogle Scholar
- Martins M, Santos B, Martins A, Viveiros M, Couto I, Cruz A, Pagès JM, Molnar J, Fanning S, Amaral L, Management Committee Members of Cost B16 European Commission/European Science Foundation: An instrument-free method for the demonstration of efflux pump activity of bacteria. In vivo 2006, 20: 657-664.Google Scholar
- Mortimer PG, Piddock LJ: A comparison of methods used for measuring the accumulation of quinolones by Enterobacteriaceae, Pseudomonas aeruginosa and Staphylococcus aureus . J Antimicrob Chemother 1991, 28: 639-653. 10.1093/jac/28.5.639View ArticleGoogle Scholar
- Viveiros M, Martins A, Paixão L, Rodrigues L, Martins M, Couto I, Fähnrich E, Kern WV, Amaral L: Demonstration of intrinsic efflux activity of Escherichia coli K-12 AG100 by an automated ethidium bromide method. Int J Antimicrob Agents 2008, 31: 458-462. 10.1016/j.ijantimicag.2007.12.015View ArticleGoogle Scholar
- Viveiros M, Martins M, Couto I, Rodrigues L, Spengler G, Martins A, Kristiansen JE, Molnar J, Amaral L: New methods for the identification of efflux mediated MDR bacteria, genetic assessment of regulators and efflux pump constituents, characterization of efflux systems and screening for inhibitors of efflux pumps. Curr Drug Targets 2008, 9: 760-778. 10.2174/138945008785747734View ArticleGoogle Scholar
- Corbett Research: Rotor-Gene 3000 Real-Time Amplification. Operator's Manual Version 4.6. Corbett Research, Sydney, Australia; 2003.Google Scholar
- Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement M100-S15. CLSI, Wayne, PA, USA; 2005.Google Scholar
- Lee A, Mao W, Warren MS, Mistry A, Hoshino K, Okumura R, Ishida H, Lomovskaya O: Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance. J Bacteriol 2000, 182: 3142-3150. 10.1128/JB.182.11.3142-3150.2000View ArticleGoogle Scholar
- Seeger MA, Diederichs K, Eicher T, Brandstätter L, Schiefner A, Verrey F, Pos KM: The AcrB efflux pump: conformational cycling and peristalsis lead to multidrug resistance. Curr Drug Targets 2008, 9: 729-749. 10.2174/138945008785747789View ArticleGoogle Scholar
- Martins M, Dastidar SG, Fanning S, Kristiansen JE, Molnar J, Pagès JM, Schelz Z, Spengler G, Viveiros M, Amaral L: Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: mechanisms for their direct and indirect activities. Int J Antimicrob Agents 2008, 31: 198-208. 10.1016/j.ijantimicag.2007.10.025View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.